Keyword: Richard Gonzalez
AbbVie is plotting a $28 billion bond sale to help fund its massive Allergan buyout, Bloomberg reports, the fourth largest in history.
AbbVie's contribution to patient assistance groups and other nonprofits skyrocketed to about $350 million in 2018, from below $100 million in 2015.
AbbVie and Allergan’s $63 billion merger was a shock to the industry, but only talking to each other kept negotiations between CEOs under wraps.
AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.
Allergan investors have been pushing for action from management, and AbbVie has been hunting for new revenue streams. Now, they're set to combine.
AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch, an analyst writes.
As spring rolls on each year, proxy filings pile up, disclosing executive pay for the prior year. And as in past years, FiercePharma has tracked the info to present the top CEO pay packages in biopharma, ranging from nearly $60 million in 2018 down to $16 million.
AbbVie's Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it's not likely to be the last.